November 25, 2019 11:20 AM ESTUpdated 11:35 AM
News Briefing

Shares of Adamis crater on CRL; Boris John­son promis­es to dou­ble de­men­tia re­search fund­ing

Kathy Wong

Editor

→ San Diego-based Adamis $ADMP saw its shares crater on the news that the FDA has re­ject­ed its ap­pli­ca­tion to mar­ket high-dose nalox­one in­jec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times